Loading…
Vaxcyte, Inc. is projected to rise to $63.32 by 2027, a +13% move from its current price of $55.96. PCVX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $54.61 | $55.95 | $57.32 | -0.02% |
| Aug 2 | $54.05 | $55.94 | $57.89 | -0.04% |
| Aug 3 | $53.62 | $55.93 | $58.33 | -0.06% |
| Aug 4 | $53.27 | $55.92 | $58.70 | -0.08% |
| Aug 5 | $52.95 | $55.90 | $59.02 | -0.10% |
| Aug 6 | $52.67 | $55.89 | $59.32 | -0.12% |
| Aug 7 | $52.41 | $55.88 | $59.59 | -0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $52.41 | $55.88 | $59.59 | -0.14% |
| Week 2 | $50.96 | $55.81 | $61.11 | -0.28% |
| Week 3 | $49.86 | $55.73 | $62.29 | -0.41% |
| Week 4 | $48.94 | $55.65 | $63.28 | -0.55% |
| Week 5 | $48.14 | $55.58 | $64.16 | -0.69% |
| Week 6 | $47.42 | $55.50 | $64.95 | -0.82% |
| Week 7 | $46.76 | $55.42 | $65.69 | -0.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Vaxcyte, Inc. is a clinical-stage vaccine innovation company that develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc.
in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte, Inc. (PCVX) is a healthcare company focused on vaccine development, with a portfolio of pneumococcal and other infectious-disease vaccine candidates.
As of now, PCVX trades around $56.04 per share, with a market capitalization listed at $8.09B and a market-rank of 1033. The stock sits in the Healthcare sector and carries a bullish technical stance in the near term.
A major floor 18.8% below — a decisive break under it would weaken the trend.
The nearest floor, 9.5% below — buyers have tended to step in here.
The nearest ceiling, 8.4% above — a clean break opens room to run.
A major ceiling 17.5% above — clearing it would confirm fresh momentum.
Key PCVX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PCVX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $54.74 | Buy | $55.00 | Buy |
| MA 10 | $55.51 | Buy | $55.40 | Buy |
| MA 20 | $56.69 | Sell | $55.50 | Buy |
| MA 50 | $52.84 | Buy | $54.73 | Buy |
| MA 100 | $55.05 | Buy | $54.00 | Buy |
| MA 200 | $52.01 | Buy | $52.67 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.96 | Neutral |
| Stoch RSI (14) | 60.83 | Neutral |
| CCI (20) | -34.10 | Neutral |
| Williams %R (14) | -41.11 | Info |
| MACD (12,26,9) | -0.47 | Sell |
| ROC (12) | -0.44 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 58.89 | Neutral |
| TRIX (15) | 0.22 | Buy |
| Awesome (5,34) | -0.25 | Sell |
| Ultimate (7,14,28) | 42.77 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 54.06 | Buy |
| ADX (14) | 12.50 | Neutral |
| ATR (14) | 1.35 | Info |
The 30-day technical picture shows bullish sentiment with the RSI at 50 and key moving averages nearby: SMA50 is $52.41 and SMA200 is $51.24.
Near-term support is at $45.42 and resistance at $60.67, with a 30-day price range from $47.89 up to $65.58.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $44.85 | $55.96 | $70.60 | 0% | Neutral | |
| $51.00 | $63.32 | $82.78 | +13% | Neutral | |
| $51.78 | $65.90 | $89.13 | +18% | Neutral | |
| $55.15 | $71.63 | $99.49 | +28% | Bullish | |
| $62.26 | $82.33 | $116.92 | +47% | Bullish | |
| $72.15 | $96.98 | $140.43 | +73% | Bullish | |
| $81.49 | $111.20 | $163.86 | +99% | Bullish | |
| $85.39 | $118.18 | $176.92 | +111% | Bullish | |
| $91.74 | $128.69 | $195.48 | +130% | Bullish | |
| $94.55 | $134.33 | $206.84 | +140% | Bullish | |
| $143.08 | $215.34 | $350.98 | +285% | Bullish | |
| $219.04 | $363.54 | $643.98 | +550% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $44.85 | $55.96 | $65.24 | +0.00% |
| August 2026 | $47.48 | $55.59 | $66.51 | -0.66% |
| September 2026 | $46.59 | $54.96 | $66.55 | -1.13% |
| October 2026 | $47.53 | $56.40 | $68.94 | +2.62% |
| November 2026 | $48.34 | $57.64 | $70.99 | +2.19% |
| December 2026 | $47.52 | $56.92 | $70.60 | -1.24% |
Click any year to see its month-by-month PCVX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Vaxcyte, Inc.'s 2026 outlook centres on $55.96, within a $44.85 to $70.60 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PCVX could reach as high as $82.78, with a base case around $63.32 and support toward $51.00 — roughly +13% from $55.96. A consolidation phase looks the most probable path here.
Expect PCVX to range from $51.78 to $89.13 through 2028. The $65.90 average target implies a +18% move from current prices. That is up +4% on the projected 2027 average. Price action looks broadly range-bound.
The PCVX price prediction for 2029 points to an average of $71.63 (low $55.15, high $99.49) — a potential gain of +28% on today's $55.96. Buyers look set to stay in control over this stretch.
In 2030, PCVX is projected to trade between $62.26 and $116.92, averaging $82.33 — a potential gain of +47% from today's $55.96. That is up +15% on the projected 2029 average. Momentum favours further upside here.
Vaxcyte, Inc.'s 2031 outlook centres on $96.98, within a $72.15 to $140.43 range. That is up +18% on the projected 2030 average. That marks a +73% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, PCVX could reach as high as $163.86, with a base case around $111.20 and support toward $81.49 — roughly +99% from $55.96. Momentum favours further upside here.
Expect PCVX to range from $85.39 to $176.92 through 2033. The $118.18 average target implies a +111% move from current prices. That is up +6% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The PCVX price prediction for 2034 points to an average of $128.69 (low $91.74, high $195.48) — a potential gain of +130% on today's $55.96. Momentum favours further upside here.
In 2035, PCVX is projected to trade between $94.55 and $206.84, averaging $134.33 — a potential gain of +140% from today's $55.96. That is up +4% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Vaxcyte, Inc.'s 2040 outlook centres on $215.34, within a $143.08 to $350.98 range. That is up +60% on the projected 2035 average. That marks a +285% change versus current levels. Momentum favours further upside here.
By 2050, PCVX could reach as high as $643.98, with a base case around $363.54 and support toward $219.04 — roughly +550% from $55.96. Buyers look set to stay in control over this stretch.
Investing $1,000 in PCVX today (≈ 17.869907 PCVX) could be worth
$6,496.43
+$5,496.43 (+550%) by 2050 · US Dollar
Based on the average projected PCVX price of $363.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PCVXwould be worth at today's price.
$1,000 invested in PCVX on Jul 30, 2025 (≈ 28.719127 PCVX) would be worth
$1,607.12
+$607.12 (+60.7%) today · 1.61× · US Dollar
Based on a PCVX entry price of $34.82 vs. today's $55.96.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $55.64 | $1,005.75 | +0.6% |
| 1 month ago | $58.13 | $962.67 | -3.7% |
| 3 months ago | $56.93 | $982.96 | -1.7% |
| 6 months ago | $53.57 | $1,044.61 | +4.5% |
| 1 year ago | $34.82 | $1,607.12 | +60.7% |
| All time (5.0y) ago | $22.48 | $2,489.32 | +148.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PCVX forecast.
Our base-case forecast reaches $110.00 around 2032.
Implied market cap at $110.00: $15.88B
The year-by-year forecast provides a path of rising averages and upside potential. In 2026 the average is $56.04 with a min of $44.85 and a max of $70.22, and ROI of 0 (sentiment NEUTRAL).
By 2030 the average is $80.74 with a max of $114.38, a min of $61.19, ROI 44.1, and sentiment BULLISH.
The forecast continues to indicate strong upside, with 2040 averaging $196.72 (max $319.08, min $131.39) and ROI 251, sentiment BULLISH, and by 2050 an average of $328.86 (max $579.06, min $199.66) with ROI 486.8 and sentiment BULLISH. These figures reflect an expanding valuation path and highlight the potential long-run upside, while noting that these are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $80.74 with ROI 44.1 and sentiment BULLISH.
Forecasts show rising averages with an average of $80.74 by 2030 and $328.86 by 2050, with ROIs of 44.1 and 486.8 respectively, and sentiment turning BULLISH in later years. These are estimates, not guarantees.
Yes. The 2026 forecast range includes a max of $70.22, and later years show higher highs (e.g., 2029 max $96.14; 2030 max $114.38), indicating a path that can exceed $60.
Current price is $56.04 and market cap is $8.09B; the rank is 1033.
2040 average is $196.72 with ROI 251 and sentiment BULLISH; 2050 average is $328.86 with ROI 486.8 and sentiment BULLISH.
Vaxcyte, Inc. Community Discussion
0Share your Vaxcyte, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.